Nothing Special   »   [go: up one dir, main page]

ATE397097T1 - Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests - Google Patents

Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests

Info

Publication number
ATE397097T1
ATE397097T1 AT04015872T AT04015872T ATE397097T1 AT E397097 T1 ATE397097 T1 AT E397097T1 AT 04015872 T AT04015872 T AT 04015872T AT 04015872 T AT04015872 T AT 04015872T AT E397097 T1 ATE397097 T1 AT E397097T1
Authority
AT
Austria
Prior art keywords
detection
multiple marker
markers
marker test
mage
Prior art date
Application number
AT04015872T
Other languages
English (en)
Inventor
Dave S B Hoon
Fukashi Doi
Andrew J Conrad
Peter Schmid
Original Assignee
Wayne John Cancer Inst
Nat Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne John Cancer Inst, Nat Genetics Inst filed Critical Wayne John Cancer Inst
Application granted granted Critical
Publication of ATE397097T1 publication Critical patent/ATE397097T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
AT04015872T 1995-03-17 1996-03-13 Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests ATE397097T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40630795A 1995-03-17 1995-03-17

Publications (1)

Publication Number Publication Date
ATE397097T1 true ATE397097T1 (de) 2008-06-15

Family

ID=23607400

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04015872T ATE397097T1 (de) 1995-03-17 1996-03-13 Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests
AT96909684T ATE270712T1 (de) 1995-03-17 1996-03-13 Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96909684T ATE270712T1 (de) 1995-03-17 1996-03-13 Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests

Country Status (6)

Country Link
US (1) US6057105A (de)
EP (2) EP0871768B1 (de)
AT (2) ATE397097T1 (de)
AU (1) AU5310296A (de)
DE (2) DE69632870T2 (de)
WO (1) WO1996029430A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0938320T3 (da) * 1996-03-26 2010-10-18 Michael S Kopreski Metode til at ud af plasma eller serum tilvejebringe ekstraheret ekstracellulært RNA for at detektere, overvåge eller vurdere cancer
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6475727B1 (en) 1997-04-11 2002-11-05 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Primers and methods for the detection of disseminated tumor cells
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6824995B1 (en) * 1998-03-03 2004-11-30 Emory University Diagnostic for metastatic prostate cancer
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
PA8482201A1 (es) 1998-09-21 2001-12-14 Mim Holdings Ltd Metodo para el tratamiento de minerales refractorios que contienen metales preciosos.
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US20090233276A1 (en) * 1998-09-22 2009-09-17 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US6579973B1 (en) * 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6387697B1 (en) 1998-12-28 2002-05-14 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6586177B1 (en) 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
WO2001040269A2 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
WO2001051664A2 (en) * 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
US7098008B2 (en) * 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
KR100374423B1 (ko) * 2000-04-25 2003-03-28 주식회사 아이씨엔지 다수의 ｍａｇｅ 아형 또는 ｇａｇｅ 아형을 인식하는암진단용 프라이머
EP1158001B1 (de) * 2000-05-26 2007-11-14 F. Hoffmann-La Roche Ag Eine Nukleinsäure, die in menschlichen Tumorzellen aufreguliert wird, ein von dieser kodiertes Protein und ein Verfahren zur Tumordiagnose
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
EP1930447A3 (de) * 2000-07-11 2008-06-25 Kirk Hogan Verfahren und Zusammensetzungen zur perioperativen genomischen Profilerstellung
US6703204B1 (en) 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
CA2439402A1 (en) * 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
AU2002303545A1 (en) * 2001-05-01 2002-11-11 Loma Linda University Surgery Medical Group, Inc. Method for identifying lymph nodes
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
CA2451074C (en) * 2001-06-18 2014-02-11 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US20040091857A1 (en) * 2001-07-20 2004-05-13 Nallur Girish N. Gene expression profiling
ATE502119T1 (de) * 2001-07-25 2011-04-15 Oncomedx Inc Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
US7247426B2 (en) 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
ES2253533T3 (es) 2001-09-06 2006-06-01 Adnagen Ag Procedimiento para la deteccion cualitativa y/o cuantitativa de celulas.
WO2003028539A2 (en) * 2001-10-01 2003-04-10 The Children's Hospital Of Philadelphia Materials and methods for the diagnosis of pediatric tumors
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
US7553619B2 (en) * 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
US7473526B2 (en) * 2002-03-29 2009-01-06 Veridex, Llc Breast cancer prognostic portfolio
EP1365034A3 (de) * 2002-05-21 2004-02-18 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren
EP1510587B1 (de) * 2002-05-21 2011-07-13 Sysmex Corporation Nukleinsäureamplifikationsprimer zum nachweis von cytokeratinen und untersuchungsverfahren mit verwendung der primer
US7897336B2 (en) 2002-08-16 2011-03-01 John Wayne Cancer Institute Molecular lymphatic mapping of sentinel lymph nodes
DE10238046A1 (de) 2002-08-20 2004-03-04 Giesing, Michael, Prof. Dr.med. Verfahren zum Untersuchen von Körperflüssigkeiten auf Krebszellen, dessen Verwendung, entsprechende Analysekits und Verwendung bestimmter Wirkstoffe zur Behandlung von Krebs
CA2498783A1 (en) * 2002-09-12 2004-03-25 Yissum Research Development Company Of The Hebrew University Of Jerusale M Method for detection of micro-metastasis
EP1572105B1 (de) 2002-11-14 2011-08-31 John Wayne Cancer Institute Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US7491814B2 (en) * 2002-11-28 2009-02-17 Peter Kufer Real-time RT-PCR for the sensitive detection of multiple MAGE gene transcripts
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US8778606B2 (en) 2003-03-04 2014-07-15 John A. Swetledge At-home cancer test
US7718364B2 (en) * 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
US8043834B2 (en) * 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
EP1757705B1 (de) * 2003-05-01 2009-01-14 Veridex LLC Intraoperativer Lymphknotentest
JP2004350685A (ja) * 2003-05-07 2004-12-16 Tosoh Corp 微小転移の検出法
TWI340168B (en) * 2003-05-07 2011-04-11 Tosoh Corp Method of detecting micrometastasis
US20040248103A1 (en) * 2003-06-04 2004-12-09 Feaver William John Proximity-mediated rolling circle amplification
WO2005055804A2 (en) * 2003-12-02 2005-06-23 Musc Foundation For Research Development Methods and compositions for diagnosing epithelial cell cancer
US20050178726A1 (en) * 2004-02-18 2005-08-18 Robert Belly Disruption of cells and tissues
WO2005084254A2 (en) * 2004-02-27 2005-09-15 Musc Foundation For Research Development Enhanced detection of rna using a panel of truncated gene-specific primers for reverse transcription
EP2290076B1 (de) 2004-05-28 2015-03-25 Asuragen, Inc. Verfahren und Zusammensetzungen mit MicroRNA
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
EP1774030A4 (de) 2004-07-09 2008-07-09 Univ Pittsburgh Identifizierung von markern bei speiseröhrenkrebs, kolonkarzinom, kopf- und halstumoren sowie melanom
WO2006031843A2 (en) * 2004-09-14 2006-03-23 John Wayne Cancer Institute Detection of cancer cells in body fluids
FR2875512B1 (fr) * 2004-09-17 2011-02-04 Diagnogene S A Biopuce de diagnostic du caractere metastatique ou localise d'une tumeur mammaire, procede et kit d'utilisation
WO2006034215A2 (en) * 2004-09-20 2006-03-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Multiple mode multiplex reaction quenching method
ES2507544T3 (es) 2004-11-12 2014-10-15 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1863908B1 (de) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
US8119352B2 (en) * 2006-06-20 2012-02-21 Cepheld Multi-stage amplification reactions by control of sequence replication times
EP2145001A2 (de) * 2006-09-19 2010-01-20 Asuragen, Inc. Von mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulierte gene und stoffwechselwege als ziele für einen therapeutischen eingriff
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
DK2104737T3 (da) * 2006-12-08 2013-05-27 Asuragen Inc Funktioner og formål for let-7 mikro-RNAer
EP2104735A2 (de) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-21-regulierte gene und pfade als ziele für therapeutische interventionen
CN101622348A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
CA2671194A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
US8197420B2 (en) 2006-12-18 2012-06-12 Magnolia Medical Technologies, Inc. Systems and methods for parenterally procuring bodily-fluid samples with reduced contamination
EP2134677B1 (de) 2006-12-20 2011-10-12 Bayer HealthCare LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
US20090186015A1 (en) * 2007-10-18 2009-07-23 Latham Gary J Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090263803A1 (en) * 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
WO2009154835A2 (en) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
US20090258928A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc. Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
US20100227319A1 (en) * 2008-06-19 2010-09-09 John Wayne Cancer Institute Use of runx3 and mir-532-5p as cancer markers and therapeutic targets
RU2579897C2 (ru) 2008-09-26 2016-04-10 Онкомед Фармасьютикалс, Инк. Агенты, связывающие рецептор "frizzled", и их применение
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
WO2010151109A1 (en) * 2009-06-26 2010-12-29 Erasmus University Medical Center Rotterdam Identifying circulating tumor cells (ctcs) using cd146 in breast cancers patients
AU2011305696A1 (en) * 2010-09-20 2013-05-02 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
SG10201602456WA (en) * 2011-08-31 2016-04-28 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US8535241B2 (en) 2011-10-13 2013-09-17 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US8864684B2 (en) 2011-10-13 2014-10-21 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
CA2852811A1 (en) 2011-11-04 2013-05-10 Royal College Of Surgeons In Ireland Adam22 for use as a prognostic variable, and target for therapy, of a metastatic breast cancer disease
US9022950B2 (en) 2012-05-30 2015-05-05 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
US9060724B2 (en) 2012-05-30 2015-06-23 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
WO2014022275A1 (en) 2012-08-01 2014-02-06 Magnolia Medical Technologies, Inc. Fluid diversion mechanism for bodily-fluid sampling
EP2906269B1 (de) 2012-10-11 2018-01-03 Magnolia Medical Technologies, Inc. System zur abgabe einer flüssigkeit an einen patienten mit reduzierter kontamination
RU2537263C2 (ru) * 2012-10-22 2014-12-27 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Нижегородский Государственный Университет Им. Н.И. Лобачевского" Способ скрининга и мониторинга онкологических заболеваний и набор для его осуществления (варианты)
WO2014066179A1 (en) * 2012-10-24 2014-05-01 Clontech Laboratories, Inc. Template switch-based methods for producing a product nucleic acid
US9155495B2 (en) 2012-11-30 2015-10-13 Magnolia Medical Technologies, Inc. Syringe-based fluid diversion mechanism for bodily fluid sampling
EP3626172B1 (de) 2012-12-04 2023-03-22 Magnolia Medical Technologies, Inc. Vorrichtung zur sterilen körperflüssigkeitsentnahme
US10772548B2 (en) 2012-12-04 2020-09-15 Magnolia Medical Technologies, Inc. Sterile bodily-fluid collection device and methods
JP6437515B2 (ja) 2013-03-12 2018-12-12 マグノリア メディカル テクノロジーズ，インコーポレイテッド 針の内腔を選択的に閉塞するための方法及び装置
EP3113747B1 (de) 2014-03-03 2019-11-27 Magnolia Medical Technologies, Inc. Vorrichtung und verfahren zur desinfektion eines probenbehälters
US11234626B2 (en) 2015-06-12 2022-02-01 Magnolia Medical Technologies, Inc. Devices and methods for syringe-based fluid transfer for bodily-fluid sampling
CN108366904B (zh) 2015-09-03 2020-12-01 木兰医药技术股份有限公司 用于维护样本容器的无菌性的设备和方法
EP3681384B1 (de) 2017-09-12 2022-12-28 Magnolia Medical Technologies, Inc. Ein system
CN110628905A (zh) * 2018-06-25 2019-12-31 武汉菲思特生物科技有限公司 一种用于乳腺原位癌的诊断标志物检测试剂盒及其检测方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458831A1 (de) * 1989-02-16 1991-12-04 BALAZS, Viktor, Dr. Dr. med. Malignitätstest (krebs-test) mit verwendung von der polymerasekettenreaktion
AU662906B2 (en) * 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
JP3399948B2 (ja) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ Ｐ９０抗体またはプローブを用いた前癌細胞または癌細胞の検出方法

Also Published As

Publication number Publication date
EP0871768A1 (de) 1998-10-21
DE69632870D1 (de) 2004-08-12
EP1505159B1 (de) 2008-05-28
AU5310296A (en) 1996-10-08
EP1505159A1 (de) 2005-02-09
EP0871768B1 (de) 2004-07-07
WO1996029430A1 (en) 1996-09-26
US6057105A (en) 2000-05-02
ATE270712T1 (de) 2004-07-15
DE69637552D1 (de) 2008-07-10
DE69632870T2 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
ATE397097T1 (de) Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests
ATE130873T1 (de) Nachweis der expression von neu genen und produkten.
ATE433498T1 (de) Detektion von neoplasien durch speichelanalyse
ES2090297T3 (es) Produccion de proteinas que utilizan recombinacion homologa.
AU647741B2 (en) Methods and compositions for chromosome-specific staining
ATE108490T1 (de) Hybridisierungssonden.
NO893583D0 (no) Amplifikasjon og paavisning av nukleinsyresekvenser.
WO2000052204A3 (en) Gene expression in bladder tumors
ES8506168A1 (es) Un metodo de detectar una secuencia de polinucleotido.
ATE109204T1 (de) Methoden zur in vitro-dna-amplifikation, zum genomischen klonieren und zur genkartierung.
ATE59185T1 (de) Die antigenischen determinanten von hbxag.
GB1466828A (en) Diagnostic test system
ES2047033T3 (es) Un metodo para preparar compuestos de hidroxivitamina d.
WO1994012881A3 (en) A method for detecting growing cells using translationally controlled tumor protein p21
DE69734236D1 (de) Genetische marker und methoden zum detektion von escherichia coli serotype-0157:h7
ATE224453T1 (de) Verwendung eines spezifischen markers zur detektion von salmonellen mit pcr
DE69734595D1 (de) Verfahren zum entdecken von telomerase-aktivität
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
AU527196B2 (en) Enzymatic method for detecting cancer in mammalian tissue
IL126257A (en) Immuno-magnetic cell separation for use in identification of genes associated with site-preferenced cancer methastasis formation
NO20032391L (no) Ekspresjonsanalyse av KIAA-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
DE68925457D1 (de) Diagnoseverfahren für infektionskrankheiten sowie verfahren zum nachweis und identifizierung von mikroorganismen
WO2000061814A8 (en) Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
DE69735676D1 (de) Proteinmarker für ösophaguskrebs
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties